康宁杰瑞制药-B(09966):KN026新辅助治疗乳腺癌III期临床研究结果获选于2026 ASCO年会 LBA口头报告环节进行展示

智通财经
Apr 22

智通财经APP讯,康宁杰瑞制药-B(09966)公布,与石药集团(01093)附属公司上海津曼特生物科技有限公司合作开发的KN026联合注射用多西他赛(白蛋白结合型)(HB1801)新辅助治疗人表皮生长因子受体2(HER2)阳性(HER2阳性)乳腺癌(BC)III期临床研究(研究编号:KN026-004)的显著性结果已获选在2026年美国临床肿瘤学会年会(2026 ASCO年会)的LBA口头报告环节进行展示。该研究由复旦大学附属肿瘤医院邵志敏教授担任主要研究者,标志着中国原研创新疗法在国际学术舞台上的重大里程碑。

KN026-004是一项随机、对照、开放、多中心III期临床研究,旨在评价KN026 联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在HER2阳性早期及局部晚期BC新辅助治疗中的疗效和安全性。研究结果显示,与目前的标准治疗方案(TCbHP)相比,KN026联合疗法显著提升了患者的总体病理完全缓解(tpCR)率。研究结果表明,首次在头对头III期临床试验中证实了HER2双特异性抗体的表现优于曲妥珠单抗与帕妥珠单抗的双单抗联合疗法,且安全性可控。 KN026联合疗法有望成为HER2阳性早期及局部晚期BC新辅助治疗的全新标准疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10